IKNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IKNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Ikena Oncology's average basic shares outstanding for the quarter that ended in Jun. 2024 was 48.26 Mil.
The historical data trend for Ikena Oncology's Shares Outstanding (Basic Average) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ikena Oncology Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Shares Outstanding (Basic Average) | 13.99 | 34.59 | 27.98 | 36.19 | 41.74 |
Ikena Oncology Quarterly Data | |||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Shares Outstanding (Basic Average) | Get a 7-Day Free Trial | 39.29 | 43.44 | 47.87 | 48.26 | 48.26 |
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
Ikena Oncology (NAS:IKNA) Shares Outstanding (Basic Average) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Be Aware
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Thank you for viewing the detailed overview of Ikena Oncology's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.
Owen Hughes | director | C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139 |
Jotin Marango | officer: CFO & Head of Corp. Dev. | C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3 |
Francisco Oliveira | officer: Principal Accounting Officer | IKENA ONCOLOGY, INC., 645 SUMMER STREET, SUITE 101, BOSTON MA 02210 |
Richard Wooster | director | C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Xiaoyan Michelle Zhang | officer: Chief Scientific Officer | C/O IKENA ONCOLOGY, INC., 645 SUMMER STREET SUITE 101, BOSTON MA 02210 |
Jean Francois Formela | director | C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451 |
Atlas Venture Fund Xi, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Maria Koehler | director | C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
David P Bonita | director | C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Mark Manfredi | director, officer: President & CEO | C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Maude Tessier | officer: Chief Business Officer | C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Jeffrey Ecsedy | officer: Chief Scientific Officer | C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Atlas Venture Associates Xi, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Associates Xi, Llc | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
From GuruFocus
By Marketwired • 08-07-2023
By sperokesalga sperokesalga • 05-15-2023
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By sperokesalga sperokesalga • 02-28-2023
By Value_Insider Value_Insider • 11-07-2022
By GuruFocus Research • 02-07-2024
By Value_Insider Value_Insider • 11-07-2022
By PurpleRose PurpleRose • 08-11-2022
By PurpleRose PurpleRose • 07-12-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.